Recent News

Asymptomatic CNS Involvement From Advanced Renal Cell Carcinoma

AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer

AACR 2021: Combination Targeted Therapies Under Study in Resistant Kidney Cancer

Do Proton Pump Inhibitors Influence Cabozantinib Outcomes in Metastatic Kidney Cancer?

Two Perspectives on One Woman’s Successful Robotic Kidney-Sparing Surgery

Prognostic Role of Sarcopenia for Targeted Therapy in Metastatic Kidney Cancer

IGLL5 Expression in Clear Cell Kidney Cancer: Potential Prognostic Biomarker?

Tivozanib Versus Sorafenib in Refractory Renal Cell Carcinoma

CLEAR Trial: Targeted Therapy Plus Immunotherapy in Advanced Renal Cell Carcinoma

Plasma KIM-1: Biomarker for Recurrence Risk After Surgery for Localized Kidney Cancer?

Advanced Renal Cell Carcinoma: Focus on Gender and Racial Differences in Treatment

FDA Grants Priority Review to HIF-2α Inhibitor for Renal Cell Carcinoma

Comparing Immunotherapy Regimens in Metastatic Kidney Cancer

FDA Approval Granted to Tivozanib for Advanced Renal Cell Carcinoma

GU Symposium 2021: Radiotherapy Plus Pembrolizumab for Oligometastatic Kidney Cancer

GU Symposium 2021: Novel mTOR1/2 Inhibitor Under Study in Metastatic Kidney Cancer

Nivolumab as Neoadjuvant Therapy in High-Risk Clear Cell Renal Cell Carcinoma

GU Symposium 2021: Updated CheckMate 9ER Results on Nivolumab Plus Cabozantinib in Kidney Cancer

Does Metastatic Tumor Shrinkage Influence Overall Survival in Renal Cell Carcinoma?

GU Symposium 2021: Cabozantinib Emerges From SWOG 1500 Trial of Metastatic Papillary Kidney Cancer

GU Symposium 2021: CLEAR Trial of Lenvatinib and Pembrolizumab or Everolimus in Kidney Cancer

Impact of the Affordable Care Act in Renal Cell Carcinoma

GU Symposium 2021: Oral HIF-2α Inhibitor Plus Cabozantinib in Advanced Kidney Cancer

GU Symposium 2021: Cabozantinib for Renal Cell Carcinoma With Brain Metastases

After Cytoreductive Nephrectomy: When Is More Treatment of Benefit?

Venous Thromboembolism at the Time of Surgery for a Renal Mass: Clinical Implications

Novel HIF-2α Inhibitor Under Study in Von Hippel-Lindau–Associated Kidney Cancer

Surgical Margin Status and Outcomes After Radical Nephrectomy

Impact of Surgical Treatment Delay on Outcomes in Renal Cell Carcinoma

Impact of Bone Metastases on Surgical Outcomes in Metastatic Kidney Cancer

SORCE Trial: Active Surveillance or Sorafenib After Surgery in Renal Cell Carcinoma?

Cabozantinib Plus Immunotherapy Under Study in Advanced Renal Cell Carcinoma

Nivolumab Plus Cabozantinib Approved by FDA for Advanced Renal Cell Carcinoma

Germline Mutations in Early-Onset Renal Cell Carcinoma

Immunotherapy After Nephrectomy Under Study in Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma: Dosage Studies of HIF-2α Inhibitor Underway

HIF-2α Inhibitor for von Hippel-Lindau Disease-Associated Clear Cell Kidney Cancer

Preclinical Study Examines Role of circRNA_001287 in Progression of Renal Cell Carcinoma

Palliative Care Utilization Trends in Advanced Renal Cell Carcinoma

Renal Cell Carcinoma and COVID-19: Does Surgical Delay Impact Outcomes?

Novel Glycolysis-Related Gene Signature Developed in Renal Cell Carcinoma

Case Study of Rare but Aggressive Immune-Related Adverse Events in Kidney Cancer

Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: OMNIVORE Trial